Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This study will determine how much ertapenem is removed by continuous hemodialysis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan
• Treatments: Ertapenem

Criteria

Inclusion Criteria:

• Hospitalized in ICU

• Receiving Continuous hemodialysis

• Prescribed ertapenem

• Informed consent granted

Exclusion Criteria:

• < 18 years of age

• Allergy to ertapenem or other carbapenem antibiotic

• Severe, life-threatening reaction to penicillin or cephalosporins

• Patients experiencing or with history of CNS disorders (eg: seizure, stroke)

• Patients experiencing CNS infection

• Inability to complete 24 hours of CVVHD

• Concurrent use of other extracorporeal therapies such as extracorporeal membrane oxygenation, plasmapheresis or intermittent hemodialysis

• Inability to obtain informed consent

• Pregnant and/or breastfeeding women